Q-omics provides the consensus-scored NUP58 profile across patient tissues and cancer cell-line models. NUP58 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, NUP58 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, NUP58 protein abundance shows 26,117 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, HNSC, and GBM as cancer lineages where NUP58 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUP58 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUP58 survival associations across molecular data types. NUP58 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUP58 RNA expression–survival associations across cancer types. High NUP58 expression shows unfavorable associations in CESC, ACC, KICH and SARC, but favorable associations in COAD and UCS. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for NUP58 RNA expression.
This table summarizes NUP58 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NUP58. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUP58 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, COAD, BLCA and STAD. The HNSC box plot shows higher NUP58 RNA expression in tumor versus normal tissue (log2 FC = +0.857, t-test p < 0.001).
This table shows molecular features associated with NUP58 in patient tissues and cancer cell lines. In patient samples, NUP58 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUP58 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
